We are international
Donate
TEXT SIZE   


Dr. Ghobrial - Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib
Irene M. Ghobrial, MD
Dana-Farber Cancer Institute
Boston, Massachusetts
12.02.10


To view the video full screen, click on the small button next to the volume control in the lower right hand corner.


 related articles